logo-loader

Shield Therapeutics: building the brand base as it progresses with Accrufer launch process

Published: 11:22 16 Nov 2021 EST

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the company has an advantage as one of the few UK-based firms marketing an approved product into the US market.

Savin telling Proactive that Accrufer, a treatment for iron deficiency or anaemia, is a premium drug. And with Shield owning the product, this means they will take all the profit and, most importantly, control the process.

Click here to read the full report

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 10/03/2023